Sundip S Karsan, MD
Gastroenterology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Karsan’s office at (408) 972-3000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A100884 · Current
Licensed to practise in California · since 2007 · expires 2028-09-30 · University of Vermont College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$1,705
Medicare paid this office $1,705 for 11 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
11 Original Medicare patients in 2024. Average age 68 · 85 and older 0% · Health risk score 1.32. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
The office billed $9,812, Medicare allowed $2,376 and paid $1,705; for 11 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 11 | 11 | 68 | 1.32 | $9,812 | $1,705 |
| 2023 | 11 | 12 | 61 | 1.69 | $11,537 | $1,962 |
| 2018 | 11 | 14 | 63 | 2.23 | $13,980 | $2,662 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Drugs they prescribed that Part D paid
$73,636
Pharmacies billed $73,636 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 387) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
342 generic and fewer than 11 brand-name prescriptions · $73,636 in drug cost · 16 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mesalamine | 14 | $22,286 | $1,592 |
| Amjevita(Cf) | 13 | $11,587 | $891 |
| Gavilyte-C | 208 | $4,786 | $23 |
| Budesonide Dr | 13 | $975 | $75 |
| Peg-3350 and Electrolytes | 15 | $408 | $27 |
See all 6 drugs
| Mesalamine | 14 | $22,286 | $1,592 |
| Amjevita(Cf) | 13 | $11,587 | $891 |
| Gavilyte-C | 208 | $4,786 | $23 |
| Budesonide Dr | 13 | $975 | $75 |
| Peg-3350 and Electrolytes | 15 | $408 | $27 |
| Omeprazole | 37 | $390 | $11 |
Year by year
| 2024 | 387 | 268 | 0% (0) | None | $73,636 |
| 2023 | 449 | 337 | 0% (0) | 20% | $110,839 |
| 2022 | 434 | 288 | 0% (0) | 29% | $212,346 |
| 2021 | 344 | 245 | 0% (0) | 19% | $109,438 |
| 2020 | 192 | 151 | 0% (0) | 29% | $61,038 |
| 2019 | 247 | 185 | 0% (0) | 14% | $44,424 |
| 2018 | 234 | 179 | 0% (0) | 45% | $55,510 |
| 2017 | 234 | 165 | 0% (0) | 13% | $53,461 |
| 2016 | 292 | 223 | 0% (0) | 17% | $36,115 |
| 2015 | 316 | 242 | 0% (0) | 7% | $27,303 |
| 2014 | 526 | 387 | 0% (0) | 9% | $49,483 |
| 2013 | 157 | 134 | 0% (0) | None | $9,955 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Mesalamine | 12 | $16,972 | $1,414 |
| Gavilyte-C | 243 | $5,176 | $21 |
| Peg-3350 and Electrolytes | 50 | $1,283 | $26 |
| Omeprazole | 35 | $355 | $10 |
| Famotidine | 12 | $115 | $10 |
2022: 6 drugs
| Lialda | 13 | $8,285 | $637 |
| Gavilyte-C | 175 | $3,226 | $18 |
| Peg-3350 and Electrolytes | 48 | $1,042 | $22 |
| Sucralfate | 18 | $610 | $34 |
| Omeprazole | 53 | $523 | $10 |
| Pantoprazole | 16 | $281 | $18 |
2021: 7 drugs
| Lialda | 13 | $7,303 | $562 |
| Budesonide Ec | 14 | $1,851 | $132 |
| Peg-3350 and Electrolytes | 82 | $1,729 | $21 |
| Gavilyte-C | 96 | $1,460 | $15 |
| Sucralfate | 14 | $847 | $60 |
| Omeprazole | 28 | $464 | $17 |
| Peg 3350-Electrolyte | 11 | $297 | $27 |
2020: 2 drugs
| Gavilyte-C | 83 | $1,610 | $19 |
| Peg-3350 and Electrolytes | 31 | $685 | $22 |
2019: 3 drugs
| Gavilyte-C | 137 | $4,983 | $36 |
| Gavilyte-G | 23 | $554 | $24 |
| Omeprazole | 14 | $282 | $20 |
2018: 3 drugs
| Gavilyte-C | 75 | $2,746 | $37 |
| Peg 3350-Electrolyte | 62 | $2,276 | $37 |
| Omeprazole | 18 | $432 | $24 |
2017: 4 drugs
| Lialda | 12 | $21,187 | $1,766 |
| Gavilyte-C | 135 | $2,307 | $17 |
| Pantoprazole | 11 | $348 | $32 |
| Omeprazole | 14 | $317 | $23 |
2016: 4 drugs
| Gavilyte-C | 177 | $3,057 | $17 |
| Omeprazole | 18 | $625 | $35 |
| Pantoprazole | 17 | $565 | $33 |
| Clarithromycin | 14 | $430 | $31 |
2015: 3 drugs
| Gavilyte-C | 204 | $3,492 | $17 |
| Omeprazole | 25 | $1,319 | $53 |
| Clarithromycin | 11 | $285 | $26 |
2014: 4 drugs
| Lialda | 11 | $13,277 | $1,207 |
| Gavilyte-C | 334 | $5,690 | $17 |
| Omeprazole | 78 | $2,888 | $37 |
| Dicyclomine | 11 | $271 | $25 |
2013: 2 drugs
| Gavilyte-C | 120 | $2,040 | $17 |
| Omeprazole | 19 | $527 | $28 |
Money from drug and device companies
$224 in 2019
A payment is not proof that care is biased.
| Takeda Pharmaceuticals U.S.A. | Entyvio | $152 | 2 payments
|
| Allergan | Linzess | $72 | 1 payment
|
See all 3 published payments
| Allergan | Meals · 2019-10-27 | Linzess | $72 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2019-10-27 | Entyvio | $52 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2019-05-19 | Entyvio | $100 |
Professional record
- NPI
- 1134300924
- Licence
- CA A100884California A100884: Current · expires 2028-09-30
- Trained
- University of Vermont College of Medicine, 2006
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 8700 Beverly Blvd, Room 5512, West Hollywood, CA, 90048
- NPI first listed
- 2007-11-20
- NPI last updated
- 2022-02-11
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.